Dermatologist in Delhi, Skin Specialist In Delhi

Dermatologist in Delhi, Skin Specialist In Delhi

Dermatologist In Delhi | Skin Specialist In Delhi

Dr. Sandesh Gupta - Dermatologist in Delhi

Dr. Sandesh Gupta


Specialties: Dermatology (Skin), Hair Transplantation, Cosmetology (Skin), botox, face and Lip Filler

Positions: Director – Skin N Laser Centre

Available at: Skin N Laser Centre, Krishna Nagar, East Delhi


  • MBBS
  • DVD
  • MCSI (Cosmetology)


  • Member of Delhi Medical Association(DMA)
  • Member of IADVL
  • Member, Cosmetic Society of India (CSI)

Expertise ( Dermatologist In Delhi )

  • Non cultured melanocyte transfer
  • Botox & Fillers
  • Cosmetic Surgery
  • Hair Transplantation by FUE and FUT Technique.
  • Liposuction of chin & Tummy.
  • Autologous fat transfer for Wrinkles.
  • Birthmark Removal
  • Hair & Nail Disorder
  • Chemical peels
  • Pigmentation Tretment
  • Breast Augmentation


Received various awards during his educational phase.


  • Clinical Trials
  • As Principal investigator.
  • A Phase II, Double-Blind, Trial of EpiCept NP-1 Topical Cream (2% Ketamine / 4% Amitriptyline) vs. Oral Gabapentin in Postherpetic Neuralgia (PHN)
  • A double-blind, placebo-controlled study to evaluate the safety, clinical efficacy and tolerability of imiquimod (2%) in cream to cure external genital warts .
  • A Phase III Safety and Efficacy Study of T1hAb administered intravenously in subjects with active moderate to severe psoriasis .
  • A Study For Evaluation of the Efficacy & Safety Of Topical Botanical Sureheal Cream & Sureheal Sterile Particles In Chronic Non-Healing ulcer.
  • A Study to compare the efficacy and evaluate safety of Clindamycin 1% / Benzoyl Peroxide 5% Topical Gel ) with Duac? Topical Gel ) in Patients with Acne Vulgaris.
  • A Study To Evaluate The HPA Axis Suppression, Efficacy And Safety Of Clobetasol Propionate Cream 0.025% Formulation 5And Clobetasol Propionate Cream 0.025% Formulation 13 As Compared To Temovate E Emollient 0.05% (Clobetasol propionate emollient cream) In Patients With Moderate To Severe Psoriasis For 28 Days.
  • A study of subcutaneous secukinumab to demonstrate efficacy after twelve weeks of treatment, compared to placebo and etanercept and to assess the safety, tolerability and long-term efficacy up to one year in subjects with moderate to severe chronic plaque-type psoriasis.
  • A study the Safety, Tolerability and Efficacy of Tinefcon in Patients With Plaque Psoriasis.
  • A Study to Evaluate the Bioequivalence of Calcipotriene Cream 0.005% (Glenmark Generics Ltd.) to Dovonex (Calcipotriene Cream) 0.005% (Leo Pharma) in patients with Moderate to Severe Plaque Psoriasis
  • A study to determine the clinical bioequivalence of a generic Clotrimazole 1% and Betamethasone Dipropionate 0.05 % Topical Cream and the reference listed Lotrisone (Clotrimazole 1% and Betamethasone Dipropionate 0.05 %) Topical Cream in subjects with Interdigital Tinea Pedis
  • As Coinvestigator:
  • A Randomized, open label, prospective, two arm, comparative multicentric study to evaluate the efficacy and safety of fixed dose combination of cefpodoxime 200 mg + Clavulanic acid 125 mg vs Cefpodoxime 200 mg in treatment of patients with acute bacterial sinusitis”.
  • A randomized, open label, active control, safety, tolerability and pharmacokinetic study of two Dr Reddys formulations of metronidazole versus immediate release metronidazole (Flagyl) in Patients with mild to moderate CDAD .